CSC’s stem cell-derived electric motor neuron item for SMA receives FDA orphan drug designation California Stem Cell, Inc. Orphan medication designation, granted by the FDA Office of Orphan Products Development, provides several incentives to companies in the private sector developing novel drugs or biologics to take care of diseases with small market potential relatively. These include seven years market exclusivity following FDA approval, clinical trial style assistance, reduced user costs and tax credits . Pre-clinical GLP security and efficacy studies, funded by the Groups of Spinal significantly Muscular Atrophy and conducted by Professor Hans S.

Other Articles From "diabetology":

Random Articles